The French government is actively considering the provision of funding for the biotechnology industry, which is hit by limited access to R&D capital in the current economic downturn (see also page 2). Investment in the sector fell 79% to 143.0 million euros ($190.4 million) in 2008, the Marketletter's European correspondent reports.
The financing is expected to come via the country's Strategic Investment Fund, the FSI, with early indications that the amount available will be less than for the automobile parts manufacturers that have received about 300.0 million euros so far. The FSI is majority-owned by the French tax authority and is intended raise 20.0 billion euros to provide minority support to companies in sensitive sectors of the economy. A total of 100.0 million euros is understood to be the likely extent of support for the country's biotechnology firms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze